Magellan joins Australian Ethical Health Alliance
Magellan Stem Cells has joined the Australian Ethical Health Alliance and is a signatory to the Australian Consensus Framework (ACF) for ethical collaboration in the healthcare sector. The Australian Ethical Health Alliance aims to strengthen healthcare delivery in Australia by encouraging a commitment to ethical practice. It seeks to facilitate ethical behaviour at the organisational […]
Magellan wins prestigious international award
Magellan Stem Cells has won the 2026 award for Most Promising Off-the-Shelf Therapy Pipeline in the Asia Pacific region. The award, presented at the Asia-Pacific Cell and Gene Therapy Excellence Awards in Singapore on 30 June, recognises Magellan’s 17 years of exceptional clinical translational research in cell therapy, along with our outstanding and well-structured clinical […]
Magellan’s donor osteoarthritis treatment gets new name
The World Health Organization has accepted “Zelestrocel” as the new name globally for Magellan Stem Cells’ donor osteoarthritis stem cell product. The change has come about after Magellan made an international non-proprietary name application under the auspices of the WHO. The new name is made up of the prefix “Zele” – which translates to “zeal” […]
Magellan COO addresses Beijing conference
Magellan Stem Cells Chief Operations Officer Nick Bleisner has addressed the 11th Immunotherapy, Gene Therapy and Cell Therapy Convention in Beijing, China, as a special guest speaker. Nick’s subject matter is one of the most critical parts of advanced cell therapy development, the scale-up and stability challenges involved in supplying a large-scale Phase III stem […]
Magellan sponsors AusBiotech International Conference gene therapy discussion
Magellan Stem Cells was delighted to take part in the AusBiotech International Conference 2025 in Melbourne where we showcased Magellan’s cell-manufacturing capabilities. Across the four days of the conference, Magellan representatives engaged with hundreds of attendees and participants. As one of the few Therapeutic Goods Administration-licenced GMP-certified CDMOs for cell therapies in Australia, Magellan has […]
Magellan researchers win major international award
Magellan Stem Cell researchers have been honoured with a Research Publication of the Year Award by a prestigious international medical journal. The Melbourne-based researchers won the Osteoarthritis and Cartilage Open Clinical Research Publication of the Year Award for the excellence of their original research. The results of Magellan’s Phase I/IIa trials of Magellan’s off-the-shelf osteoarthritis […]
Dr Nirali Shah Named Joint Kingston Woman of the Year 2025
Magellan Stem Cells congratulates Dr Nirali Shah, our Laboratory Senior Scientist, who has been named joint Kingston Woman of the Year 2025 in recognition of her outstanding contribution to science and the community. Read the full article on the City of Kingston website: https://www.kingston.vic.gov.au/council/news/latest-news/women-of-the-year-2025-winners
Health Minister announces a $7 million grant to Magellan Stem Cells
Last night on 10 News First (see the news report here), the Australian Government’s Health Minister The Hon Mark Butler announced a $7 million grant to Magellan Stem Cells to help deliver a Phase III human trial for our donor stem cell treatment for osteoarthritis. The minister said: “Osteoarthritis is a huge cause of pain […]
Magellan Update April 2024
AGM AND TOUR OF FACILITY The Magellan Stem Cells Annual General Meeting of was held in December at the Braeside premises where Magellan Chair, Lou Panaccio conducted a fruitful meeting for those in attendance and those online. Several investors joined us after the meeting for a tour of the impressive new facility which was well […]